Phase 3 Trial Comparing Modified FOLFIRINOX to Capecitabine or Gemcitabine as Additional Chemotherapy After Surgery for Ampullary Adenocarcinoma
Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-07-11
294
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Ampullary adenocarcinoma is a rare type of digestive cancer that affects the ampulla of Vater. Surgery is currently the only curative option, but about 4% of patients experience cancer recurrence within 2 years after surgery. This phase 3 trial is studying two chemotherapy approaches given after surgery to reduce the chance of cancer returning. The study compares a new combination treatment called modified FOLFIRINOX mFOLFIRINOX against standard treatments with either capecitabine or gemcitabine.
Participants will be randomly assigned to one of two groups. Group A will receive mFOLFIRINOX every two weeks for 12 cycles 24 weeks, consisting of oxaliplatin, irinotecan, 5-fluorouracil, and folinic acid. Group B will receive either capecitabine or gemcitabine chosen by the investigator, administered over 24 weeks in specified schedules. Quality of life questionnaires and biological assessments will be conducted before and during treatment. Additional exams will occur every three months.
During the study, participants will undergo regular evaluations including scans, lab tests, and questionnaires to monitor their health and treatment effects. Disease-free survival will be assessed for up to 36 months to measure how long patients remain free of cancer recurrence. Safety and treatment responses will be closely followed throughout treatment and after completion. The total time in the study includes treatment and follow-up periods extending over several years.
CONDITIONS
Brief Title
PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma
Research Team
G
Gaël ROTH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
High liver enzymes (AST or ALT > 2.5x normal) or alkaline phosphatase > 2.5x normal at least 15 days after resection
Poor nutritional status (albumin < 30 g/dl)
Recent myocardial infarction within 6 months, severe coronary artery disease, or heart failure
Active or severe infections
Recent use of strong cytochrome P450 inhibitors or St John's Wort
Treatment with brivudine within 4 weeks prior to study
QT/QTc interval longer than 450 msec for men and 470 msec for women
Allergy to study drugs or their components
Live vaccines within 28 days prior to randomization
Other cancers treated within the last 5 years except certain skin or cervical cancers
Chronic bowel disease requiring treatment or intestinal obstruction
Pregnant or breastfeeding women
Persons under guardianship
Inability to comply with medical follow-up due to geographic, social, or psychological reasons
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 24 weeks
Participants receive adjuvant chemotherapy with either modified FOLFIRINOX every 2 weeks for 12 cycles (24 weeks) or capecitabine or gemcitabine for 24 weeks as chosen by the investigator.
Treatment visits every 2 weeks for mFOLFIRINOX or cycles lasting 2 to 3 weeks for capecitabine or gemcitabine
Follow-up
Duration - Up to 36 months after treatment
Participants are monitored with paraclinical examinations every 3 months and quality of life questionnaires before, during, and after treatment, with biological assessments before and between treatment courses as needed.
Every 3 months visits for paraclinical examinations and periodic assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Safety and Effectiveness of Total Pancreatectomy With Islet Autotransplantation for Treating Resectable Pancreas Region Adenocarcinoma at High Risk of Postoperative Fistula
Evaluating Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases in Pancreatic and Duodenal Adenocarcinoma Patients A Prospective Observational Study
Phase 3 Trial Comparing Modified FOLFIRINOX to Capecitabine or Gemcitabine as Additional Chemotherapy After Surgery for Ampullary Adenocarcinoma
ADAPTA Study Adjuvant Chemotherapy After Surgery for Ampullary Adenocarcinoma
Tailored Treatment by Cancer Subtype to Improve Survival
Phase 2 Trial Comparing Standard Therapy With and Without Sequential Cytoreductive Procedures for Metastatic Foregut Adenocarcinoma Patients With Undetectable ctDNA
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.